Resources - RESEARCH LITERACY
Spotting pseudoscience in longevity and biohacking content
Longevity pseudoscience sells mouse results, mechanisms or testimonials as proof of human benefit. Ask who was studied, what was measured and who repeated it.
Pseudoscience in longevity and biohacking content usually gives itself away in the same few ways. It takes a result from cells, worms or mice and sells it as a human lifespan benefit, it offers a plausible mechanism in place of an outcome, and it leans on testimonials, blood markers or one study instead of trials that measured health or survival in people. The most useful habit is to ask three questions of every claim: who was studied, what was measured, and has anyone else found the same thing?
Longevity is unusually exposed to this problem because the outcome people care about, living longer and staying well for longer, takes decades to measure in humans. So the field runs on proxies: lifespan in short-lived animals, changes in blood tests, and personal stories. None of these is worthless, but none of them is the answer. The examples below are real cases where the proxy and the outcome came apart.
Does extending lifespan in mice mean it works in people?
Not on its own. Mouse lifespan studies are a sensible first step, and some are very well run. One US research effort tests each compound at three separate sites in genetically mixed mice, so a result has to survive more than one lab. In a 2011 report in the Journal of Gerontology, rapamycin extended median survival by an average of 10% in male mice and 18% in females. Resveratrol and simvastatin, tested the same way, had no significant effect on survival in either sex.
Even a solid mouse result is a hypothesis about people, not a finding. A 2007 systematic review in the BMJ compared treatment effects in animal experiments with clinical trials for six conditions where the human answer was already known. Corticosteroids showed benefit in animal models of head injury but no benefit in clinical trials. Tirilazad improved neurobehavioural scores by 48% in animal models of stroke, yet in patients with stroke it was associated with a worse outcome. The authors suggested the gap may come from bias in the animal studies or from animal models failing to mimic the human disease. When content says something is proven to extend lifespan and the evidence is mice, that is the gap it is skipping.
What happened with resveratrol?
Resveratrol, the compound found in grapes and red wine, is a useful case because it was promoted for years as a longevity molecule. Much of the excitement came from studies in lower organisms. The mouse result above was one check. Another came from people. The InCHIANTI study followed 783 adults aged 65 or over in two villages in Tuscany for nine years and measured resveratrol breakdown products in their urine. Published in JAMA Internal Medicine in 2014, it found no association between resveratrol levels and death from any cause, inflammation markers, heart disease or cancer.
Be fair about what that study can and cannot say. It looked at levels from an ordinary diet, not from supplements, and it was observational. It does not prove resveratrol does nothing. What it shows is that the leap from a result in yeast or worms to the red wine molecule that slows ageing was never backed by human outcome data. Content that still makes that leap is selling a story the evidence has not caught up with.
Is "it's an antioxidant" good evidence?
A mechanism tells you why something might work. It does not tell you that it does. The antioxidant story is the sharpest example. The idea that free radicals damage cells and antioxidants mop them up is real chemistry, and it made antioxidant vitamin pills look like an obvious route to a longer life. Then the trials came in. A 2012 Cochrane review pooled 78 randomised trials with 296,707 participants. In the 56 trials at low risk of bias, antioxidant supplements were linked to a small increase in deaths, and beta-carotene and vitamin E on their own appeared to raise mortality. The reviewers found no evidence to support antioxidant supplements for prevention.
So when a longevity post spends most of its length on pathways such as mTOR, sirtuins, NAD+ or autophagy, and very little on what happened to people who took the thing, notice the swap. A mechanism diagram is not an outcome.
Why do even good longevity studies disagree?
Because long studies are hard and small design choices matter. Two teams ran parallel calorie restriction studies in rhesus monkeys over two decades. In 2009, the Wisconsin National Primate Research Center reported in Science that at the time of its report, 50% of the normally fed monkeys were still alive compared with 80% of the restricted monkeys. In 2012, the National Institute on Aging team reported in Nature that its calorie restriction regimen had not improved survival. The NIA authors suggested that study design, husbandry and diet composition may strongly affect the result.
Neither team was peddling pseudoscience. But content that cites only the Wisconsin paper and presents calorie restriction as proven to extend primate life is cherry-picking. Honest writing about a contested question tells you it is contested.
When is a longevity clinic claim a warning sign?
When it sells an unproven procedure to paying customers as if it were established medicine. In February 2019 the US Food and Drug Administration warned consumers about businesses in several states offering infusions of plasma from young donors, at up to thousands of dollars per infusion, for conditions ranging from normal ageing to memory loss. The FDA said there was no proven clinical benefit for these uses, and that plasma infusion can carry infectious, allergic, respiratory and cardiovascular risks.
The cost of trusting a confident clinic can be severe. A 2017 report in the New England Journal of Medicine described three patients who had injections of "stem cells" taken from their own fat into both eyes at a US stem cell clinic, for age-related macular degeneration. All three developed severe vision loss. A year later their sight ranged from 20/200 to no light perception at all.
A quick checklist for any longevity claim
- Who was it tested in? Cells, worms and mice generate ideas. Only human studies tell you about humans.
- What was measured? A change in a blood marker or a biological age score is not the same as living longer or staying healthier.
- Is the evidence a mechanism or an outcome? A pathway story with no outcome data is still a hypothesis.
- How many independent groups found it? One lab, one study or a founder's own data is a starting point, not a conclusion.
- Are the contradicting studies mentioned? If a claim has a well-known null result, such as the NIA monkey study or the Cochrane antioxidant review, honest content will tell you about it.
- Who is selling what? When the person explaining the science also sells the product, test or clinic visit, read more carefully.
- Is the promise in proportion to the evidence? Large, fast effects on ageing should come with large, independent human trials. Ask to see them.
None of this means longevity research is fake. The rapamycin mouse work, the monkey studies and the antioxidant trials are all real science, done carefully, and they are how we learned what does and does not hold up. Pseudoscience is what happens when someone keeps the exciting first step and quietly drops the rest.
This article is for education about how to judge evidence. It is not medical advice and does not assess any product, so speak to a qualified healthcare professional about your own health.
Frequently asked
- What are the warning signs of pseudoscience in longevity content?
- The common signs are claims that jump from cells or mice straight to human lifespan, long explanations of mechanisms with no data on what happened to people, reliance on testimonials or a single study, and silence about results that contradict the claim. Content written by someone selling the product, test or clinic visit deserves extra care.
- If something extends lifespan in mice, will it work in humans?
- Not necessarily. Animal results are a sensible first step but often fail to carry over. A 2007 BMJ review found treatments that looked helpful in animal models, such as tirilazad for stroke, did not help patients or were linked to worse outcomes in clinical trials. A mouse result is a reason to run human studies, not a substitute for them.
- Do antioxidant supplements slow ageing?
- The trial evidence does not support it. A 2012 Cochrane review of 78 randomised trials with nearly 300,000 participants found no evidence that antioxidant supplements prevent death, and in the better-quality trials beta-carotene and vitamin E appeared to slightly increase mortality. A plausible mechanism did not turn into a real-world benefit.
- Is a better biomarker or biological age score proof that something works?
- No. A change in a blood marker or an ageing score is a proxy. It may or may not track the outcomes that matter, such as illness and survival. The antioxidant story shows how a sensible-looking mechanism can point one way while trials that counted deaths point the other. Treat marker changes as early clues, not proof.
The studies and sources behind this page
- Miller RA, Harrison DE, Astle CM, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 2011;66(2):191-201.
- Perel P, Roberts I, Sena E, et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 2007;334(7586):197.
- Semba RD, Ferrucci L, Bartali B, et al. Resveratrol levels and all-cause mortality in older community-dwelling adults. JAMA Intern Med 2014;174(7):1077-84.
- Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2012;(3):CD007176.
- Colman RJ, Anderson RM, Johnson SC, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009;325(5937):201-4.
- Mattison JA, Roth GS, Beasley TM, et al. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 2012;489(7415):318-21.
- US Food and Drug Administration. Important information about young donor plasma infusions for profit. 19 February 2019.
- Kuriyan AE, Albini TA, Townsend JH, et al. Vision loss after intravitreal injection of autologous "stem cells" for AMD. N Engl J Med 2017;376(11):1047-53.
Lessons on this topic
Related reading
Educational content only. Not medical advice, diagnosis or treatment. Always consult a qualified healthcare professional before changing your health regimen.